Gotham Asset Management LLC Has $48.72 Million Stock Position in Biogen Inc. $BIIB

Gotham Asset Management LLC raised its stake in Biogen Inc. (NASDAQ:BIIB) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 276,809 shares of the biotechnology company’s stock after buying an additional 6,311 shares during the period. Gotham Asset Management LLC owned 0.19% of Biogen worth $48,716,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. WPG Advisers LLC boosted its position in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares in the last quarter. Accredited Wealth Management LLC boosted its position in Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares in the last quarter. First Horizon Corp acquired a new stake in Biogen in the fourth quarter valued at approximately $30,000. WFA of San Diego LLC acquired a new stake in Biogen in the second quarter valued at approximately $32,000. Finally, Root Financial Partners LLC boosted its position in Biogen by 198.4% in the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on BIIB shares. Sanford C. Bernstein cut their target price on shares of Biogen from $201.00 to $200.00 in a research report on Thursday, April 30th. Argus raised shares of Biogen to a “hold” rating in a research note on Thursday, April 9th. HC Wainwright reaffirmed a “buy” rating on shares of Biogen in a research report on Thursday, May 14th. Piper Sandler reaffirmed an “overweight” rating and set a $225.00 target price (up from $214.00) on shares of Biogen in a research report on Friday, May 15th. Finally, Needham & Company LLC raised Biogen from a “hold” rating to a “buy” rating and set a $255.00 target price for the company in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Biogen has a consensus rating of “Moderate Buy” and a consensus target price of $216.70.

Biogen Price Performance

BIIB stock opened at $198.67 on Thursday. The firm has a market cap of $29.33 billion, a price-to-earnings ratio of 21.32 and a beta of 0.20. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97. The company’s fifty day simple moving average is $190.05 and its 200 day simple moving average is $184.70.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. Biogen’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, analysts expect that Biogen Inc. will post 13.89 earnings per share for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.